Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1158 related articles for article (PubMed ID: 30793644)

  • 1. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in CAR T Therapy for Hematologic Malignancies.
    Freyer CW; Porter DL
    Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
    Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
    J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
    Yang C; Nguyen J; Yen Y
    J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management Principles Associated With Cytokine Release Syndrome.
    Baer B; Dudley CV; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
    Tedesco VE; Mohan C
    J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.